1. Home
  2. BWXT vs UTHR Comparison

BWXT vs UTHR Comparison

Compare BWXT & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BWXT
  • UTHR
  • Stock Information
  • Founded
  • BWXT 1867
  • UTHR 1996
  • Country
  • BWXT United States
  • UTHR United States
  • Employees
  • BWXT N/A
  • UTHR N/A
  • Industry
  • BWXT
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • BWXT
  • UTHR Health Care
  • Exchange
  • BWXT Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • BWXT 15.4B
  • UTHR 20.7B
  • IPO Year
  • BWXT N/A
  • UTHR 1999
  • Fundamental
  • Price
  • BWXT $198.08
  • UTHR $455.08
  • Analyst Decision
  • BWXT Buy
  • UTHR Buy
  • Analyst Count
  • BWXT 11
  • UTHR 12
  • Target Price
  • BWXT $175.07
  • UTHR $495.08
  • AVG Volume (30 Days)
  • BWXT 1.6M
  • UTHR 586.0K
  • Earning Date
  • BWXT 11-03-2025
  • UTHR 10-29-2025
  • Dividend Yield
  • BWXT 0.50%
  • UTHR N/A
  • EPS Growth
  • BWXT 10.60
  • UTHR 16.08
  • EPS
  • BWXT 3.34
  • UTHR 26.38
  • Revenue
  • BWXT $3,058,850,000.00
  • UTHR $3,128,400,000.00
  • Revenue This Year
  • BWXT $17.47
  • UTHR $13.68
  • Revenue Next Year
  • BWXT $10.23
  • UTHR $5.63
  • P/E Ratio
  • BWXT $59.52
  • UTHR $17.02
  • Revenue Growth
  • BWXT 14.01
  • UTHR 13.50
  • 52 Week Low
  • BWXT $84.21
  • UTHR $266.98
  • 52 Week High
  • BWXT $218.50
  • UTHR $479.50
  • Technical
  • Relative Strength Index (RSI)
  • BWXT 50.16
  • UTHR 60.85
  • Support Level
  • BWXT $185.00
  • UTHR $444.04
  • Resistance Level
  • BWXT $216.93
  • UTHR $456.41
  • Average True Range (ATR)
  • BWXT 7.74
  • UTHR 14.30
  • MACD
  • BWXT -2.56
  • UTHR 0.60
  • Stochastic Oscillator
  • BWXT 40.51
  • UTHR 62.81

About BWXT BWX Technologies Inc.

BWX Technologies Inc is a specialty manufacturer and service provider of nuclear components, operating in two segments: Government Operations and Commercial Operations. The Government Operations segment produces naval nuclear reactors and fuel for the U.S. Naval Nuclear Propulsion Program, while the Commercial Operations segment designs and manufactures commercial nuclear steam generators, heat exchangers, pressure vessels, reactor components, and other auxiliary equipment, including containers for the storage of spent nuclear fuel and other high-level nuclear waste. The majority of the company's revenue comes from Government Operations, with sales principally in the United States, Canada, and other regions.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: